top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

David Berger Biography and Net Worth

EVP of Tandem Diabetes Care

David Berger has served as our Executive Vice President, Chief Business Operations and Compliance Officer & Secretary since November 2020 and is responsible for the Company’s legal, quality, regulatory, clinical and customer technical support functions. He previously served as Executive Vice President, Chief Legal and Compliance Officer since April 2019, and as General Counsel, having overseen the legal department since August 2013. From January 2008 until August 2013, Mr. Berger was employed at Senomyx, Inc., a taste science company, where he most recently served as Senior Vice President and General Counsel. He also served as Corporate Secretary of Senomyx from January 2008 until May 2014. From April 2003 until October 2007, Mr. Berger was responsible for all commercial aspects of legal affairs at Biosite Incorporated, or Biosite, a provider of medical diagnostic products, most recently serving as Vice President, Legal Affairs. Previously, Mr. Berger was an attorney at Cooley Godward LLP and Amylin Pharmaceuticals, Inc. Mr. Berger holds a BA in Economics from the University of California, Berkeley and a JD from Stanford Law School.

What is David B. Berger's net worth?: The estimated net worth of David B. Berger is at least $118,178.80 as of March 3rd, 2023. Mr. Berger owns 3,365 shares of Tandem Diabetes Care stock worth more than $118,179 as of April 24th. This net worth estimate does not reflect any other investments that Mr. Berger may own. Additionally, Mr. Berger receives an annual salary of $543,380.00 as EVP at Tandem Diabetes Care. Learn More about David B. Berger's net worth.
How old is David B. Berger?: Mr. Berger is currently 54 years old. There are 8 older executives and no younger executives at Tandem Diabetes Care. The oldest executive at Tandem Diabetes Care is Mr. John F. Sheridan, President, CEO & Director, who is 69 years old. Learn More on David B. Berger's age.
What is David B. Berger's salary?: As the EVP of Tandem Diabetes Care, Inc., Mr. Berger earns $543,380.00 per year. There are 2 executives that earn more than Mr. Berger. The highest earning executive at Tandem Diabetes Care is Mr. John F. Sheridan, President, CEO & Director, who commands a salary of $988,350.00 per year. Learn More on David B. Berger's salary.
How do I contact David B. Berger?: The corporate mailing address for Mr. Berger and other Tandem Diabetes Care executives is 11075 ROSELLE STREET, San Diego CA, 92121. Tandem Diabetes Care can also be reached via phone at (858) 366-6900 and via email at [email protected]. Learn More on David B. Berger's contact information.
Has David B. Berger been buying or selling shares of Tandem Diabetes Care?: David B. Berger has not been actively trading shares of Tandem Diabetes Care during the past quarter. Most recently, David B. Berger sold 10,000 shares of the business's stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $41.19, for a transaction totalling $411,900.00. Following the completion of the sale, the chief operating officer now directly owns 3,365 shares of the company's stock, valued at $138,604.35. Learn More on David B. Berger's trading history.
Who are Tandem Diabetes Care's active insiders?: Tandem Diabetes Care's insider roster includes David Berger (EVP), Kim Blickenstaff (Director), Elizabeth Gasser (EVP), Brian Hansen (EVP), James Leal (SVP), Kathleen McGroddy-Goetz (Director), Susan Morrison (EVP), Rebecca Robertson (Director), John Sheridan (CEO), Christopher Twomey (Director), and Leigh Vosseller (CFO). Learn More on Tandem Diabetes Care's active insiders.
Are insiders buying or selling shares of Tandem Diabetes Care?: In the last twelve months, Tandem Diabetes Care insiders bought shares 6 times. They purchased a total of 27,150 shares worth more than $635,045.95. The most recent insider tranaction occured on November, 27th when Director Dick Allen bought 5,000 shares worth more than $94,800.00. Insiders at Tandem Diabetes Care own 2.5% of the company. Learn More about insider trades at Tandem Diabetes Care.
Information on this page was last updated on 11/27/2023.

David B. Berger Insider Trading History at Tandem Diabetes Care

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/3/2023	Sell	10,000	$41.19	$411,900.00	3,365
12/16/2022	Sell	10,000	$40.25	$402,500.00	3,029
6/8/2022	Sell	10,097	$65.02	$656,506.94	2,457
3/16/2022	Sell	5,000	$108.37	$541,850.00
3/1/2022	Sell	1,000	$112.68	$112,680.00
2/1/2022	Sell	1,000	$117.91	$117,910.00
1/3/2022	Sell	1,000	$149.16	$149,160.00
12/15/2021	Sell	12,000	$144.25	$1,731,000.00
12/1/2021	Sell	1,000	$128.44	$128,440.00
11/1/2021	Sell	1,000	$135.70	$135,700.00
10/1/2021	Sell	1,000	$118.00	$118,000.00
9/15/2021	Sell	9,000	$121.99	$1,097,910.00
5/28/2021	Sell	3,619	$86.47	$312,934.93	6,488
5/18/2021	Sell	201	$89.14	$17,917.14	4,862
3/11/2021	Sell	8,646	$90.22	$780,042.12	13,212
10/13/2020	Sell	5,000	$119.25	$596,250.00	9,566
7/6/2020	Sell	2,000	$101.65	$203,300.00	5,886
5/4/2020	Sell	2,000	$78.33	$156,660.00	3,961
4/6/2020	Sell	2,000	$67.59	$135,180.00	5,311
1/16/2020	Sell	8,000	$67.83	$542,640.00	11,311
9/3/2019	Sell	2,000	$72.00	$144,000.00	5,311
8/5/2019	Sell	2,000	$62.56	$125,120.00	5,311
7/3/2019	Sell	2,000	$63.60	$127,200.00	5,311
6/3/2019	Sell	2,000	$67.76	$135,520.00	5,311
5/3/2019	Sell	2,000	$63.09	$126,180.00	3,765
4/3/2019	Sell	2,000	$62.60	$125,200.00	3,765
1/8/2019	Sell	10,000	$40.08	$400,800.00	11,765
12/6/2018	Sell	11,493	$34.54	$396,968.22	11,765
11/13/2013	Buy	2,000	$15.00	$30,000.00

David B. Berger Buying and Selling Activity at Tandem Diabetes Care

Tandem Diabetes Care Company Overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Today's Range

Now: $35.12

$34.36

$35.56

50 Day Range

MA: $30.51

$22.55

$35.41

2 Week Range

Now: $35.12

$13.82

$40.74

Volume

997,284 shs

Average Volume

1,735,416 shs

Market Capitalization

$2.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

From Traders Agency | Ad

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

David Berger Biography and Net Worth

What is David B. Berger's net worth?

How old is David B. Berger?

What is David B. Berger's salary?

How do I contact David B. Berger?

Has David B. Berger been buying or selling shares of Tandem Diabetes Care?

Who are Tandem Diabetes Care's active insiders?

Are insiders buying or selling shares of Tandem Diabetes Care?